ReviewExperimental dermatology2026
Melasma: When Dermal Photoageing Precedes Melanocyte Ageing.
Review in Experimental dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Melasma is a chronic relapsing hyperpigmentary disorder with difficult long-term management. In this review, melasma is proposed as a disorder of persistent melanocyte activation sustained within a photoaged dermal microenvironment. This microenvironment, composed of senescent fibroblasts, UV-activated sebocytes and vascular components, functions as a dermal melanogenic field that continuously provides melanogenic signalling. We further propose that melasma may arise within a melanogenic window, a phase characterized by a photoaged dermis and melanocytes that remain responsive to melanogenic stimulation. This window may result from dermal ageing preceding melanocyte ageing. This asynchronous cellular ageing may explain the characteristic midlife onset, chronic relapsing course and later life attenuation of melasma. From a therapeutic perspective, effective long-term management of melasma may require not only suppression of persistent melanocyte activation but also modulation of the photoaged dermal microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.